IRCT20191209045671N3招募中3 期
Evaluation of the effectiveness of Empagliflozin on metabolic factors and liver function tests in type 2 diabetic patients with non-alcoholic fatty liver, a clinical trial study
Semnan University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 years 至 65 years（—）
- 性别
- All
入选标准
- •All type 2 diabetic patients with non-alcoholic fatty liver
- •Having the consent to participate in the study
- •Age between 20 to 65 years
- •Healthy physical status
排除标准
- •history of taking SGLT2 inhibitors
- •being pregnant for women
- •history of malignancy and diseases such as AIDS and hepatitis
研究者
相似试验
尚未招募
3 期
Assessment of effectiveness of Empagliflozin in the management of Anemia in diabetes patientsCTRI/2024/02/063292SRM Insitute of Science and Technology
招募中
4 期
The effect of empagliflozin in patients with idiopathic edemaIdiopathic edema.Edema, unspecifiedR60.9IRCT20230314057712N1Ahvaz University of Medical Sciences70
已完成
3 期
Effect of Empagliflozin in prevention of kidney stone parametersIRCT20211203053261N2Hamedan University of Medical Sciences138
尚未招募
3 期
Evaluation of the effect of Empagliflozin on the severity of heart failure symptoms and echocardiography parameters in patients with congenital heart diseases with left-to-right shuntIRCT20120520009801N11Mashhad University of Medical Sciences44
招募中
3 期
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90